Results 121 to 130 of about 259,973 (348)

An Inflammation‐Targeting Engineered Probiotic Escherichia coli Nissle 1917 with High Anti‐TNF‐α Nanobody Secretion Efficacy Alleviates Ulcerative Colitis

open access: yesAdvanced Science, EarlyView.
Ulcerative colitis therapy requires precise drug targeting. This study engineers a probiotic E. coli Nissle 1917 to surface‐display ANXA5, enabling specific binding to phosphatidylserine (PS) exposed on inflamed colonic epithelium for enhanced targeting and colonization.
Siqi Hua   +6 more
wiley   +1 more source

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression

open access: yesHepatology, EarlyView., 2022
Improved mitochondrial activity, due to the lack of methylation‐controlled J protein (MCJ), creates a specific microbiota signature that when transferred through cecal microbiota transplantation delays NASH progression by restoring the gut‐liver axis and enhancing hepatic fatty acid oxidation.
María Juárez‐Fernández   +18 more
wiley   +1 more source

A Pill That Prints‐An Ingestible Bioprinter for Non‐Invasive Structured Bioink Deposition

open access: yesAdvanced Science, EarlyView.
A first‐of‐a‐kind swallowable bioprinter performs in‐situ bioink deposition and patterning directly over disease sites without tethers, electronics, or invasive surgery. Combining magnetic guidance with near‐infrared triggering enables functionality within a small footprint.
Sanjay Manoharan, Vivek Subramanian
wiley   +1 more source

Development and Clinical Evaluation of a Multiplexed Health Surveillance Panel Using Ultra High‐Throughput PRM‐MS in an Inflammatory Bowel Disease Cohort

open access: yesAngewandte Chemie, EarlyView.
Validating biomarkers of disease is necessary for clinical use. The Health Surveillance Panel (83 peptides from 57 proteins) was developed as a PRM assay and evaluated using the Stellar‐MS platform. The assay was validated with a large clinical cohort of inflammatory bowel disease patients alongside quality controls.
Qin Fu   +18 more
wiley   +2 more sources

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

open access: yesHepatology, EarlyView., 2022
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole   +12 more
wiley   +1 more source

The Stressor Factors and Perceived Social Support in the Patients with Ulcerative Colitis

open access: yesمجله دانشکده پزشکی اصفهان, 2011
• Background: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized with chronic inflammation of mucosal surface of bowels. Genetic, immunologic, environmental and individual factors contribute disease have been identified in ...
Hamid Afshar   +4 more
doaj  

Dendrobium Officinale‐Derived Carbon Dots Nanozymes Alleviate Colitis by Orchestrating Intestinal Mucus‐Epithelium‐Immune Barriers

open access: yesAdvanced Science, EarlyView.
Dendrobium officinale‐derived carbon dots (DO‐CDs) exhibiting enzyme‐mimetic activities are synthesized via a hydrothermal approach. In the colitis model, DO‐CDs effectively facilitated the repair of mucosal, epithelial, and immune barriers by upregulating the expression of mucins and tight junction proteins, as well as re‐establishing intestinal ...
Chenxi Xu   +11 more
wiley   +1 more source

Biomedical Applications of Nanozymes: An Enzymology Perspective

open access: yesAngewandte Chemie, EarlyView.
With a lens of enzymology, this review compares nanozymes with enzymes using the Michaelis‐Menten model and differences in KM and kcat along with catalysis in complex biological environment. The implications of these differences in biomedical applications of nanozymes are then described with a statistical analysis of the trend of therapeutic use of ...
Vasily G. Panferov   +4 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy